Clinical trials: Liver Cancer, Lung Cancer, Pancreatic Cancer
- Condition Liver Cancer, Lung Cancer, Pancreatic Cancer
- Funder type Industry (pharma, biotech, devices)
Sarcoma, Carcinoma
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
20 participants are expected to be enrolled for this open，Single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with advanced solid tumors.
- Conditions
- Sarcoma, Carcinoma, Breast Cancer, Pancreatic Cancer
- Trial name
- NCT05860374
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai Yunying Medical Technology
Breast Cancer, Lung Cancer
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
To characterize the safety and tolerability of NIS793 as single agent and in combination with PDR001 and to identify recommended doses for future studies.
- Conditions
- Breast Cancer, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer
- Trial name
- NCT02947165
- Testing
- NIS793, PDR001
- Where
- 12 sites in United States, Austria and 7 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Ovarian Cancer, Pancreas Cancer
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma.
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma
- Trial name
- NCT06582017
- Testing
- QXL138AM Injection every 2 weeks by IV Infusion
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Nammi Therapeutics Inc
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Breast Cancer, Glioma
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer
The purpose of this study is to assess the safety and effectiveness of natural killer (NK) cell and natural killer T (NKT) cell-based autologous adoptive immunotherapy in subjects with metastatic, treatment-refractory breast…
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00909558
- Testing
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Envita Medical Center, Inc.
Colorectal Cancer, Pancreatic Adenocarcinoma
Circulating Tumor DNA Exposure in Peripheral Blood
This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the…
- Conditions
- Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT03517332
- Where
- 6 sites in United States, Switzerland
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Quantgene Inc.
Gastrointestinal Cancer, Prostate Cancer
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
The purpose of the study is to evaluate the efficacy and the safety of AMT2003 in cancer patients with advanced disease. The primary evaluation criterion is clinical benefit response.
- Conditions
- Gastrointestinal Cancer, Prostate Cancer, Genital Neoplasms, Female
- Trial name
- NCT00332280
- Testing
- AMT2003
- Where
- 2 sites in Bosnia and Herzegovina, Germany
- Volunteers
- 67 people
- Sponsor
- Auron Healthcare GmbH
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
- Trial name
- NCT05208762
- Testing
- PF-08046054, pembrolizumab
- Where
- 62 sites in United States, Belgium and 9 more
- Volunteers
- 714 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Lung Cancer, Head and Neck Cancer
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
- Conditions
- Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Bladder Cancer
- Trial name
- DELFI-L101 (NCT04825834)
- Testing
- Blood Sample Collection
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 2,992 people
- Sponsor
- Delfi Diagnostics Inc.
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Breast Cancer, Lung Cancer
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03662204
- Testing
- Blood Sample Collection
- Where
- 119 sites in United States
- Volunteers
- 5,133 people
- Sponsor
- Exact Sciences Corporation
Ovarian Cancer, Fallopian Tube Cancer
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
This is a Phase I study to test the safety, pharmacokinetics and effectiveness of STM 434 alone, or in combination with liposomal doxorubicin, in patients with ovarian cancer or other advanced solid tumors.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
- Trial name
- NCT02262455
- Testing
- STM 434, Liposomal doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Santa Maria Biotherapeutics